NCT03925701招募中3 期
Clinical Study Evaluating the Effectiveness of Vildagliptin Versus Vildagliptin/Metformin on NAFLD With DM
Sherief Abd-Elsalam1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2019年4月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- number of patients with improved nafld and insulin resistance
研究概览
简要总结
Clinical study evaluating vildagliptin versus vildagliptin/metformin on NAFLD with DM.
详细描述
Clinical study evaluating vildagliptin versus vildagliptin/metformin on nonalcoholic fatty liver disease with DM.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •NAFLD and type 2 DM
排除标准
- •Viral hepatitis.
- •Child score more than
- •renal impairment.
研究组 & 干预措施
vildagliptin
Experimental
vildagliptin 50 mg twice daily
干预措施: Vildagliptin (Drug)
vildagliptin\metformin
Active Comparator
vildagliptin\metformin twice daily
干预措施: vildagliptin\metformin (Drug)
结局指标
主要结局
number of patients with improved nafld and insulin resistance
时间窗: 6 months
number of patients showing improved nafld and insulin resistance
次要结局
未报告次要终点
研究者
Sherief Abd-Elsalam
Ass. Prof. Tropical Medicine
Tanta University
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Metformin Versus Vildagliptin for Diabetic Hypertensive PatientsReducing the Elevated Blood Pressure for Diabetic Hypertensive PatientsNCT03253562MTI University120
已完成
3 期
Efficacy and Safety of Vildagliptin Compared to Metformin in Elderly Drug Naive Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT00383578Novartis Pharmaceuticals335
已完成
4 期
Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM)Type 2 Diabetes MellitusNCT01196546Novartis161
终止
4 期
Comparison of Vildagliptin vs. Glimepiride on Glucose Variability in Metformin Uncontrolled Type 2 Diabetic PatientsType 2 Diabetes MellitusNCT01910441Novartis Pharmaceuticals95
已完成
4 期
Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery DiseaseIschemic Heart DiseaseType 2 Diabetes MellitusNCT01604213Sheba Medical Center60